Ambarella Inc: Form 10-Q for the period ended Jul 31, 2023
Filed with the SEC on Sep 8, 2023 and accepted by EDGAR at Sep 8, 2023, 13:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-05-01 to 2023-07-31 | $62.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-02-01 to 2023-07-31 | $124.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-05-01 to 2023-07-31 | $23.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-02-01 to 2023-07-31 | $48.3m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-05-01 to 2023-07-31 | $38.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-02-01 to 2023-07-31 | $76.0m | us-gaap:GrossProfit |
| Research and development | 3 months2023-05-01 to 2023-07-31 | $54.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-02-01 to 2023-07-31 | $109.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-05-01 to 2023-07-31 | $18.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-02-01 to 2023-07-31 | $37.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-05-01 to 2023-07-31 | −$35.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-02-01 to 2023-07-31 | −$70.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-05-01 to 2023-07-31 | −$3.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-02-01 to 2023-07-31 | −$1.8m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-05-01 to 2023-07-31 | −$31.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-02-01 to 2023-07-31 | −$67.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-05-01 to 2023-07-31 | −$0.79 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-02-01 to 2023-07-31 | −$1.70 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-05-01 to 2023-07-31 | −$0.79 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-02-01 to 2023-07-31 | −$1.70 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-05-01 to 2023-07-31 | 39,736,704 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-02-01 to 2023-07-31 | 39,538,748 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-02-01 to 2023-07-31 | $15.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-02-01 to 2023-07-31 | $7.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2023-07-31 | $122.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-07-31 | $286.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-07-31 | $696.2m | us-gaap:Assets |
| Current liabilities | At period end2023-07-31 | $74.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-07-31 | $93.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-07-31 | $602.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-047207. Last ingested by Listed: Oct 30, 2026, 13:39 ET. Listed shows no prices and gives no investment advice.